NSIM
IMUC

North Star Investment Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

North Star Investment Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-500
Closed -$39K – 295
2013
Q2 		$39K Buy
+500
New +$47.9K 0.01% 277

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

North Star Investment Management's IMUC Position: Q3 2013 in Review

North Star Investment Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2013, closing a stake of 500 shares — an estimated $39K sold.

North Star Investment Management first reported a position in IMUC in Q2 2013 and held it in 1 quarter. The position peaked at $39K in Q2 2013. 37 funds tracked by Wall St. Rank hold IMUC as of Q3 2013.

  • North Star Investment Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2013 after selling out during the quarter.
  • North Star Investment Management sold 500 ImmunoCellular Therapeutics, Ltd. shares in Q3 2013, an estimated $39K.
  • North Star Investment Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 1 quarter.
  • North Star Investment Management's ImmunoCellular Therapeutics, Ltd. position peaked at $39K in Q2 2013.
  • 37 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2013.

Based on North Star Investment Management's 13F filing for Q3 2013, filed 6 Nov 2013.